Related Experiment Video
Updated: Jul 28, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Risk Factors and Prognostic Implications of New-Onset Paroxysmal Atrial Fibrillation in Patients Hospitalized with
Baozi Huang1,2, Jianle Li1, Pingping Li1,2
1Department of Neurology and Stroke Center, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, The First Affiliated Hospital, Sun Yat-sen University, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, People's Republic of China.
Insights
New-onset paroxysmal atrial fibrillation (PAF) after intracranial hemorrhage (ICH) is linked to older age, larger hematoma volume, and heart failure. This new-onset PAF independently predicts poor functional outcomes.
Area of Science:
- Neurology
- Cardiology
- Internal Medicine
Background:
- Intracranial hemorrhage (ICH) is a severe neurological event.
- Paroxysmal atrial fibrillation (PAF) is a common cardiac arrhythmia.
- The relationship between ICH and new-onset PAF, and its impact on outcomes, requires further investigation.
Purpose of the Study:
- To determine the prevalence and risk factors of new-onset paroxysmal atrial fibrillation (PAF) in patients hospitalized with intracranial hemorrhage (ICH).
- To assess whether new-onset PAF influences functional outcomes in ICH patients.
Main Methods:
- Analysis of a consecutive patient database with ICH from October 2013 to May 2022.
- Univariate and multivariable regression analyses to identify risk factors for new-onset PAF.
- Multivariate models to evaluate new-onset PAF as a predictor of functional outcome using the modified Rankin scale.
Main Results:
- Among 650 ICH patients, 24 developed new-onset PAF.
- Independent risk factors for new-onset PAF included older age, larger hematoma volume, and heart failure.
- New-onset PAF was an independent predictor of poor functional outcome (OR, 10.35 [95% CI, 1.08-98.80]; P=0.042).
Conclusions:
- Older age, larger hematoma volume, and heart failure are independent risk factors for new-onset PAF post-ICH.
- Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) correlates with increased risk.
- New-onset PAF significantly predicts poor functional outcomes in ICH survivors.
Objective:
We aimed to assess the prevalence and risk factors of new-onset paroxysmal atrial fibrillation (PAF) in patients hospitalized with ICH and determine whether the new-onset PAF had influenced functional outcomes.
Methods:
We analyzed a database of all consecutive patients with ICH from October 2013 to May 2022. Univariate and multivariable regression analyses were performed to identify risk factors for new-onset PAF in patients with ICH. Multivariate models were also constructed to assess whether the new-onset PAF was an independent predictor of poor functional outcome, as measured using the modified Rankin scale.
Results:
This study included 650 patients with ICH, among whom 24 patients had new-onset PAF. In the multivariable model, older age (OR per 10-y increase, 2.26 [95% CI, 1.52-3.35]; P<0.001), hematoma volume (OR per 10-mL increase, 1.80 [95% CI, 1.26-2.57]; P=0.001), and heart failure (OR, 21.77 [95% CI, 5.52-85.91]; P<0.001) were independent risk factors for new-onset PAF. In a sensitivity analysis restricted to 428 patients with N-terminal pro-B-type natriuretic peptide (NT-proBNP), older age, larger hematoma volume, heart failure, and increased NT-proBNP were associated with new-onset PAF. After adjusting for baseline variables, new-onset PAF was an independent predictor of poor functional outcome (OR, 10.35 [95% CI, 1.08-98.80]; P=0.042).
Conclusion:
Older age, larger hematoma volume, and heart failure were independent risk factors for new-onset PAF after ICH. Increased NT-proBNP is correlated with higher risks for new-onset PAF when their information is available at admission. Furthermore, new-onset PAF is a significant predictor of poor functional outcome.
More Related Videos
Related Concept Videos
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins